Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke
© 2023 Published by Elsevier Inc..
Background: Anti-NMDA-receptor GluN1 antibodies (NMDAR1-abs) are present in an autoimmune encephalitis with severe neuropsychiatric symptoms. We aimed to estimate the impact of serum NMDAR1-abs on depressive symptoms years after first-ever ischemic stroke (IS).
Methods: Data were used from the PROSpective Cohort with Incident Stroke-Berlin (PROSCIS-B; NCT01363856). Serum NMDAR1-abs (IgM/IgA/IgG) were measured within 7 days after IS using cell-based assays. We defined seropositivity as titers ≥1:10, thereof low titers as ≤1:100 and high titers as >1:100. We used the Center for Epidemiological Studies-Depression (CES-D) scale to measure depressive symptoms at year one, two and three following IS. We calculated crude and confounder adjusted weighted generalized linear models to quantify the impact of NMDAR1-abs on CES-D assessed at three annual time-points.
Results: NMDAR1-abs were measured in 583 PROSCIS-B IS patients (mean age = 67 [SD = 13]; 42%female; median NIHSS = 2 [IQR = 1-4]) of whom 76 (13%; IgM: n = 49/IgA: n = 43/IgG: n = 2) were seropositive, 55 (9%) with low and 21 (4%) with high titers. CES-D regarded over all follow-up time-points was higher in seropositive patients (βcrude = 2.56 [95%CI = -0.34 to 5.45]; βadjusted = 2.26 [95%CI = -0.68 to 5.20]) and effects were highest in patients with high titer (low titers: βcrude = 1.42 [95%CI = -1.79 to 4.62], βadjusted = 0.53 [95%CI = -2.47 to 3.54]; high titers: βcrude = 5.85 [95%CI = 0.20 to 11.50]; βadjusted = 7.20 [95%CI = 0.98 to 13.43]).
Conclusion: Patients with serum NMDAR1-abs (predominantly IgM&IgA) suffer more severe depressive symptoms after mild-to-moderate IS compared to NMDAR1-abs seronegative patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Brain, behavior, & immunity - health - 34(2023) vom: 14. Dez., Seite 100705 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sperber, Pia S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Revised 02.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.bbih.2023.100705 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365247405 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365247405 | ||
| 003 | DE-627 | ||
| 005 | 20231226101249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbih.2023.100705 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365247405 | ||
| 035 | |a (NLM)38033615 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sperber, Pia S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Published by Elsevier Inc. | ||
| 520 | |a Background: Anti-NMDA-receptor GluN1 antibodies (NMDAR1-abs) are present in an autoimmune encephalitis with severe neuropsychiatric symptoms. We aimed to estimate the impact of serum NMDAR1-abs on depressive symptoms years after first-ever ischemic stroke (IS) | ||
| 520 | |a Methods: Data were used from the PROSpective Cohort with Incident Stroke-Berlin (PROSCIS-B; NCT01363856). Serum NMDAR1-abs (IgM/IgA/IgG) were measured within 7 days after IS using cell-based assays. We defined seropositivity as titers ≥1:10, thereof low titers as ≤1:100 and high titers as >1:100. We used the Center for Epidemiological Studies-Depression (CES-D) scale to measure depressive symptoms at year one, two and three following IS. We calculated crude and confounder adjusted weighted generalized linear models to quantify the impact of NMDAR1-abs on CES-D assessed at three annual time-points | ||
| 520 | |a Results: NMDAR1-abs were measured in 583 PROSCIS-B IS patients (mean age = 67 [SD = 13]; 42%female; median NIHSS = 2 [IQR = 1-4]) of whom 76 (13%; IgM: n = 49/IgA: n = 43/IgG: n = 2) were seropositive, 55 (9%) with low and 21 (4%) with high titers. CES-D regarded over all follow-up time-points was higher in seropositive patients (βcrude = 2.56 [95%CI = -0.34 to 5.45]; βadjusted = 2.26 [95%CI = -0.68 to 5.20]) and effects were highest in patients with high titer (low titers: βcrude = 1.42 [95%CI = -1.79 to 4.62], βadjusted = 0.53 [95%CI = -2.47 to 3.54]; high titers: βcrude = 5.85 [95%CI = 0.20 to 11.50]; βadjusted = 7.20 [95%CI = 0.98 to 13.43]) | ||
| 520 | |a Conclusion: Patients with serum NMDAR1-abs (predominantly IgM&IgA) suffer more severe depressive symptoms after mild-to-moderate IS compared to NMDAR1-abs seronegative patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibodies | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Ischemia | |
| 650 | 4 | |a N-Methyl-D-Aspartate | |
| 650 | 4 | |a Prospective studies | |
| 650 | 4 | |a Receptors | |
| 650 | 4 | |a Stroke | |
| 700 | 1 | |a Gebert, Pimrapat |e verfasserin |4 aut | |
| 700 | 1 | |a Broersen, Leonie H A |e verfasserin |4 aut | |
| 700 | 1 | |a Kufner, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Shufan |e verfasserin |4 aut | |
| 700 | 1 | |a Piper, Sophie K |e verfasserin |4 aut | |
| 700 | 1 | |a Teegen, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Heuschmann, Peter U |e verfasserin |4 aut | |
| 700 | 1 | |a Prüss, Harald |e verfasserin |4 aut | |
| 700 | 1 | |a Endres, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Liman, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Siegerink, Bob |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain, behavior, & immunity - health |d 2020 |g 34(2023) vom: 14. Dez., Seite 100705 |w (DE-627)NLM307291391 |x 2666-3546 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g day:14 |g month:12 |g pages:100705 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbih.2023.100705 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |b 14 |c 12 |h 100705 | ||